Lyell Immunopharma, Inc.
LYEL
$12.90
$0.201.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -71.43% | -45.45% | -55.88% | -38.46% | 133.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -71.43% | -45.45% | -55.88% | -38.46% | 133.33% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -71.43% | -45.45% | -55.88% | -38.46% | 133.33% |
| SG&A Expenses | -31.97% | -26.90% | -9.19% | -20.15% | 4.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -34.47% | 7.38% | -117.95% | -37.09% | -27.60% |
| Total Operating Expenses | -21.08% | -0.44% | -26.26% | -15.98% | 0.94% |
| Operating Income | 21.07% | 0.43% | 26.24% | 15.97% | -0.93% |
| Income Before Tax | 53.73% | 26.68% | 12.87% | 6.82% | 13.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.73% | 26.68% | 12.87% | 6.82% | 13.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.73% | 26.68% | 12.87% | 6.82% | 13.96% |
| EBIT | 21.07% | 0.43% | 26.24% | 15.97% | -0.93% |
| EBITDA | 20.34% | -4.17% | 24.31% | 13.87% | -4.15% |
| EPS Basic | 68.79% | 49.98% | 38.88% | 19.56% | 25.87% |
| Normalized Basic EPS | 67.98% | 7.63% | 38.88% | 26.81% | 10.88% |
| EPS Diluted | 68.79% | 49.98% | 38.88% | 19.56% | 25.87% |
| Normalized Diluted EPS | 67.98% | 7.63% | 38.88% | 26.81% | 10.88% |
| Average Basic Shares Outstanding | 48.26% | 46.56% | 42.55% | 15.84% | 16.07% |
| Average Diluted Shares Outstanding | 48.26% | 46.56% | 42.55% | 15.84% | 16.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |